First cohort for Kevetrin dosing chosen. First dosing to occur this week. . . the time is NOW!
First cohort for Kevetrin dosing chosen. First dosing to
Top 10 Most Recent News Articles
Rosalind Franklin University’s $23.8M Scholarship Win
Twenty-three million dollars can disappear fast in graduate health education, which is exactly why Rosalind Franklin University’s campaign result deserves more than a polite round of applause. The university’s five-year Empowering Scholars effort closed in June 2026 with $23,836,272 raised, clearing its $20 million target by roughly 19%. In a world where institutions...
Continue Reading
Danaher and Microsoft Put AI Into the Lab Stack Early
Laboratory AI gets interesting only when it reaches the hardware bench, and Danaher is taking a serious swing at that ugly, complicated job with Microsoft. The Nov. 20 partnership is not just another chatbot bolted onto a dashboard. It is aimed at building a common agentic platform that can help instruments interpret scientific intent, guide setup, control hardware within...
Continue Reading
CCTV-4 Revisits China's Enduring Academy Tradition
Stone courtyards, old books and hard questions are getting prime time on CCTV-4, which is a more interesting programming bet than it may first appear. Enduring Chinese Academies, a ten-episode cultural exploration series from China Media Group's Global Chinese Programming Center, is built around a simple theme: “One academy, one spirit.” It begins airing November 22...
Continue Reading
Neurelis Founder Earns EY's 2026 Top Entrepreneur Honor
Some business awards are wallpaper; this one carries real clinical weight. EY US named Craig Chambliss, CEO and co-founder of Neurelis, its Entrepreneur Of The Year 2026 National Overall Award winner. In a sector where plenty of companies talk grandly about changing lives and then vanish into the regulatory fog, the underlying story matters more than the trophy. Neurelis...
Continue Reading
Oatly’s $4.13 Tender Offer Is a Legal Detour, Not a Sale
A $4.13 cash offer trading against a $7.17 close is the sort of thing that makes investors squint hard, and Verlinvest is practically waving a flag telling them why. This is not a conventional attempt to buy Oatly Group AB. It is a technical tender offer built to satisfy Swedish takeover rules while Verlinvest buys out its joint-venture partner’s interest in Oatly’s...
Continue Reading
Surgery Partners Deal Faces Fresh Price Scrutiny Ahead
A $23.50 cash offer can look wonderfully tidy until somebody asks how the number was built. That is where Surgery Partners shareholders find themselves after Halper Sadeh LLC said it is investigating the proposed sale of Surgery Partners, Inc. to HealthSpan Partners. The firm is examining whether the company’s board obtained a fair price, ran a conflict-free process,...
Continue Reading
CITGO Sign Return Caps Kenmore's Careful Rebuild Work
Thirty feet upward and 120 feet eastward is not the sort of move that usually stops a city in its tracks, yet Boston’s CITGO Sign was never merely rooftop hardware. Its public relighting in Kenmore Square marks the final phase of the redevelopment at 660 Beacon Street, and the real accomplishment is less flashy than the lights: a beloved, federally landmarked object...
Continue Reading
Sports Leagues Confront Youth Gambling's Hard Truth
A stadium-sized advertising machine cannot pretend kids are not watching. That is the uncomfortable backdrop to the National Council on Problem Gambling's November 10 youth gambling prevention summit, where representatives from the NFL, MLB, NBA and PGA Tour met at the NFL's New York offices. Good that they showed up. Frankly, with gambling stitched into so much sports...
Continue Reading
University of Phoenix Poll Gets a Useful Reality Check
Good Numbers, With the Usual Fine Print Employer approval is the kind of evidence career-focused schools desperately need, and University of Phoenix just put up a pretty loud batch of it. Among managers who directly supervise its graduates, 94% said the university understands employer needs, while 92% said its programs align with workforce demands. Those are stout...
Continue Reading
PexarBolt's CES Honor Meets a Real Crowdfunding Test
A little touchscreen bolted onto a dock would usually make me roll my eyes. This time, Pexar has at least put enough muscle behind the gimmick to deserve a harder look. The PexarBolt Ultra TBT5 Dock was named a CES Innovation Awards 2027 Honoree in Computer Peripherals & Accessories, following an IFA 2026 Innovation Awards honor only two months after its launch. Awards do...
Continue ReadingTop 5 Most Recently Viewed Articles
Deere & Co's Future Amid Repair Debates and Financial Insights
Barclays Reconfirms Target for Deere & Co Barclays recently reaffirmed its Overweight rating on Deere & Co (NYSE: DE) and maintained a $400 price target, amidst an ongoing dialogue surrounding the right to repair. This discussion has re-emerged in the spotlight, temporarily impacting Deere's share price before it regained ground. The analyst noted that this issue has been...
Continue Reading
Inventor Offers Hospital Sign to Prevent Infections
A Fresh Take on Infection Control Some days you stumble across an idea that just clicks—like the latest gadget for hospitals. Forget complex systems or high-tech cameras; this is about a simple sign that screams 'stop!' before you walk into trouble. It’s designed to safeguard hospital staff by alerting them to take precautions before entering rooms with infectious...
Continue Reading
JPMorgan Adjusts NOV Stock Outlook Amidst Market Challenges
JPMorgan Adjusts NOV Stock Outlook Recently, JPMorgan made changes to its financial outlook for NOV Inc. (NYSE: NOV), a key player in the energy equipment and services sector. The investment firm lowered its price target from $23 to $22 but maintained an Overweight rating on the stock. This adjustment was driven by expectations of a slowdown in North American operations...
Continue Reading
Madrigal Pharmaceuticals Expands Workforce with Incentive Awards
Madrigal Pharmaceuticals Strengthens Workforce with New Grants Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a leading biopharmaceutical company dedicated to innovative treatments for metabolic dysfunction-associated steatohepatitis (MASH), has recently taken a significant step to bolster its team. The company announced granting equity inducement awards to 76 new...
Continue Reading
Pomerantz Investigates Investor Claims Against Abacus Global Management
Pomerantz Law Firm's Investigation into Abacus Global Management In recent news, the Pomerantz Law Firm has embarked on an investigation regarding Abacus Global Management, Inc. (NASDAQ: ABL). This investigation revolves around potential securities fraud and other unlawful business practices committed by the company and some of its executive members. For investors...
Continue Reading